680 filings
Page 17 of 34
6-K
fvwrae ln
25 Oct 18
RedHill Biopharma to Present at the BIO-Europe 2018 Conference
8:00am
6-K
11obp9 pi82j
24 Oct 18
RedHill Biopharma Announces Final Patient Assessed in Confirmatory Phase III Study with TALICIA® for H. pylori Infection
8:01am
6-K
nxsre
22 Oct 18
Current report (foreign)
9:26am
6-K
mxcvo57f
10 Oct 18
RedHill Biopharma Late-Breaking Abstract on Positive Phase III Crohn’s Disease Study with RHB-104 to be Presented at UEG Week 2018
7:00am
6-K
5uqv2qu2k
20 Sep 18
RedHill Biopharma to Present at Ladenburg Thalmann 2018 Healthcare Conference
7:00am
6-K
0tw1dujrxp0qyxz 6ybf
12 Sep 18
RedHill Biopharma Announces Positive End-of-Phase II Meeting with FDA on BEKINDA® for IBS-D
12:00am
6-K
cqybwhma
6 Sep 18
RedHill Biopharma Announces Advancement to Second Stage of Phase IIa Study with YELIVA® for Cholangiocarcinoma
12:00am
6-K
y80mepojbv0ng 3kytk4
4 Sep 18
RedHill Biopharma Announces Completion of Enrollment for Confirmatory Phase III Study with TALICIA® for H. pylori Infection
12:00am
6-K
pvacc
30 Aug 18
Current report (foreign)
12:00am
6-K
oeh by4ksn
24 Aug 18
Current report (foreign)
12:00am
6-K
kzgdl27h 87dg7cwo
20 Aug 18
RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-106, an Encapsulated Bowel Preparation
12:00am
6-K
yaylh8
14 Aug 18
RedHill Biopharma Announces Closing of $25 Million Underwritten Offering
10:17am
6-K
47e9961 cseuf
13 Aug 18
Current report (foreign)
12:30pm
6-K
l1s513faxvkdi
13 Aug 18
RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-104 for Crohn’s Disease and RHB-204 for NTM Infections
7:00am
6-K
l3wve
9 Aug 18
RedHill Biopharma Announces Pricing of $25 Million Underwritten Offering
9:10am
6-K
q5hwmdu nueexjcb
1 Aug 18
RedHill Biopharma Elaborates on Its Announced Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease
8:18am
6-K
vg70mh
30 Jul 18
RedHill Biopharma Announces Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease
12:00am
6-K
xn38 njvy
25 Jul 18
Current report (foreign)
8:00am
6-K
eithl 9ns32
24 Jul 18
RedHill Biopharma Enrolls 400th Patient in Confirmatory Phase III Study with TALICIA® for H. pylori Infection
8:23am
6-K
6r0zl1cl6jtz3exhb
23 Jul 18
RedHill Biopharma Announces Uplisting to Nasdaq Global Market
7:15am